Poor outcomes have been reported to be significantly associated with the expression of B7-H3 in individuals suffering from breast cancer, osteosarcoma (OS), cervical cancer, esophageal squamous cancer, gallbladder cancer, CRC, prostate cancer, lung cancer, and RCC (Ni and Dong, 2017[44]). Here, CD276 is linked to osteosarcoma.